RecruitingPHASE1, PHASE2NCT05386108

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Studying Multiple endocrine neoplasia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Stemline Therapeutics, Inc.
Intervention
Elacestrant(drug)
Enrollment
73 enrolled
Eligibility
18 years · All sexes
Timeline
20222026

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05386108 on ClinicalTrials.gov

Other trials for Multiple endocrine neoplasia

Additional recruiting or active studies for the same condition.

See all trials for Multiple endocrine neoplasia

← Back to all trials